Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study

Published:2023-08-29 Issue: Volume: Page:1-10
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Lai Xin¹^ORCID,Wan Qing¹,Jiao Shou-Feng¹,Sun Xiao-Chun¹,Hu Jin-Fang¹,Peng Hong-Wei¹

Affiliation:

1. Department of Pharmacy, First Affiliated Hospital of Nanchang University, Nanchang, China

Funder

National Natural Sciences Foundation Committee

Jiangxi Provincial Key Research and Development Plan

Clinical Pharmaceutical Research Fund of the China International Medical Exchange Foundation

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2251398

Reference44 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options

3. A global view of hepatocellular carcinoma: trends, risk, prevention and management

4. Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview

5. Epidemiology and Management of Hepatocellular Carcinoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database;British Journal of Clinical Pharmacology;2024-09-02

2. Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms;Journal of Molecular and Cellular Cardiology;2024-09

3. Adverse events of tissue plasminogen activators in acute myocardial infarction patients: a real-world and pharmacovigilance database analysis;BMC Cardiovascular Disorders;2024-08-23

4. A Novel Combinatorial Regimen Using Sorafenib and Uttroside B, A US FDA-designated ‘Orphan Drug’, for the Treatment of Hepatocellular Carcinoma;Anti-Cancer Agents in Medicinal Chemistry;2024-08-09

5. Hepatocellular carcinoma, vascular endothelial growth factor receptors‐targeting agents, and hypertension: A much more complicated relationship than expected;Cancer;2024-01-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3